Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938847 | 0.93 | FPR2 (0.36) | FFAR4FEN1DGAT1FPR2ALOX5AP | |
| SCHEMBL12836496 | 0.93 | FPR2 (0.33) | FFAR4CNR2SCN9AFEN1DGAT1 | |
| SCHEMBL11939798 | 0.90 | FFAR4 (0.36) | FFAR4CNR2SCN9AFEN1DGAT1 | |
| SCHEMBL11939321 | 0.89 | FFAR4 (0.33) | FFAR4DGAT1GRIN1GRIN2BFPR2 | |
| SCHEMBL11939353 | 0.89 | CNR2 (0.36) | CNR2SCN9AFEN1ALOX5AP | |
| SCHEMBL11939325 | 0.89 | CNR2 (0.36) | CNR2SCN9AFEN1ALOX5AP | |
| SCHEMBL15381702 | 0.88 | FFAR4 (0.39) | FFAR4SCN9AFEN1DGAT1GRIN1 | |
| SCHEMBL10303143 | 0.87 | HTR2A (0.38) | CNR2SCN9AFFAR1 | |
| SCHEMBL10303129 | 0.87 | FFAR1 (0.39) | CNR2FFAR1 | |
| SCHEMBL12223491 | 0.86 | CNR2 (0.38) | CNR2SCN9AFEN1ALOX5APFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FFAR4 1038/4885CNR2 474/4885SCN9A 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.